Androgen signaling plays an important role in many biological processes. Androgen Responsive Gene Database (ARGDB) is devoted to providing integrated knowledge on androgen-controlled genes. Gene records were collected on the basis of PubMed literature collections. More than 6000 abstracts and 950 original publications were manually screened, leading to 1785 human genes, 993 mouse genes, and 583 rat genes finally included in the database. All the collected genes were experimentally proved to be regulated by androgen at the expression level or to contain androgen-responsive regions. For each gene important details of the androgen regulation experiments were collected from references, such as expression change, androgen-responsive sequence, response time, tissue/cell type, experimental method, ligand identity, and androgen amount, which will facilitate further evaluation by researchers. Furthermore, the database was integrated with multiple annotation resources, including National Center for Biotechnology Information, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes pathway, to reveal the biological characteristics and significance of androgen-regulated genes. The ARGDB web site is mainly composed of the Browse, Search, Element Scan, and Submission modules. It is user friendly and freely accessible at http://argdb.fudan.edu.cn. Preliminary analysis of the collected data was performed. Many disease pathways, such as prostate carcinogenesis, were found to be enriched in androgen-regulated genes. The discovered androgen-response motifs were similar to those in previous reports. The analysis results are displayed in the web site. In conclusion, ARGDB provides a unified gateway to storage, retrieval, and update of information on androgen-regulated genes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419166 | PMC |
| http://dx.doi.org/10.1210/me.2009-0103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression and clinical significance of lncRNA PART1 in patients with unexplained recurrent pregnancy loss.
Gynecol Endocrinol
December 2024
Department of Reproductive Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, P.R. China.
Article Synopsis
- This study investigated the role of lncRNA PART1 as a potential biomarker for unexplained recurrent pregnancy loss (URPL) and its link to poor pregnancy outcomes in affected women.
- The research analyzed plasma and endometrial tissue samples from 60 women with URPL and 15 healthy controls, finding that PART1 transcript variant 2 was significantly higher in the URPL group.
- Results indicated that high levels of PART1 expression were associated with negative pregnancy outcomes, suggesting it could be a risk factor, warranting further investigation into its relationship with URPL.
The SPARC-related modular calcium binding 1 (Smoc1) regulated by androgen is required for mouse gubernaculum development and testicular descent.
Asian J Androl
August 2024
Department of OB/GYN, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Article Synopsis
- Testicular descent occurs in two stages: the transabdominal and inguinoscrotal stages, with androgens being crucial, especially in the second stage to help develop the gubernaculum, which guides the testis into the scrotum.
- A study on Lhcgr KO mice showed that the gene Smoc1 was significantly suppressed without androgens but was strongly induced by testosterone, indicating its importance in gubernaculum development.
- SMOC1 not only promotes the proliferation of gubernacular cells but also works alongside testosterone to enhance myogenic markers, suggesting it plays a key role in mediating the effects of androgens during testicular descent.
The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.
J Med Virol
March 2024
School of Life Sciences, University of Essex, Colchester, UK.
The sex disparity in COVID-19 outcomes with males generally faring worse than females has been associated with the androgen-regulated expression of the protease TMPRSS2 and the cell receptor ACE2 in the lung and fueled interest in antiandrogens as potential antivirals. In this study, we explored enzalutamide, an antiandrogen used commonly to treat prostate cancer, as a potential antiviral against the human coronaviruses which cause seasonal respiratory infections (HCoV-NL63, -229E, and -OC43). Using lentivirus-pseudotyped and authentic HCoV, we report that enzalutamide reduced 229E and NL63 entry and infection in both TMPRSS2- and nonexpressing immortalized cells, suggesting a TMPRSS2-independent mechanism.
View Article and Find Full Text PDFAcetylated KHSRP impairs DNA-damage-response-related mRNA decay and facilitates prostate cancer tumorigenesis.
Mol Oncol
September 2024
Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Androgen-regulated DNA damage response (DDR) is one of the essential mechanisms in prostate cancer (PCa), a hormone-sensitive disease. The heterogeneous nuclear ribonucleoprotein K (hnRNPK)-homology splicing regulatory protein known as far upstream element-binding protein 2 (KHSRP) is an RNA-binding protein that can attach to AU-rich elements in the 3' untranslated region (3'-UTR) of messenger RNAs (mRNAs) to mediate mRNA decay and emerges as a critical regulator in the DDR to preserve genome integrity. Nevertheless, how KHSRP responds to androgen-regulated DDR in PCa development remains unclear.
View Article and Find Full Text PDFTherapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer.
Cancers (Basel)
November 2023
Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA.
Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen therapies (NGAT) including enzalutamide, abiraterone acetate, apalutamide, and darolutamide; taxane therapy represented by docetaxel; and PARP inhibitors (PARPi) like olaparib. Although these treatments have shown efficacy and have improved outcomes for many patients, some do not survive due to the emergence of therapeutic resistance. The clinical landscape is further complicated by limited knowledge about how the sequence of treatments impacts the development of therapeutic cross-resistance in CRPC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!